Mar 22 • 31M

Ep. 43 - The hype behind Wegovy

How medical weight loss could alter America's public health

 
1×
0:00
-31:22
Open in playerListen on);
    Substack App
    Download MP3
    Get a private RSS link for listening
    Subscribe to The FLATLINING Podcast to get a private link for listening in your favorite podcast player. Learn about RSS.

Appears in this episode

Matthew Handley
Ron Howrigon
The FLATLINING Podcast brings you great healthcare analysis and discussion each week from industry experts who know their way around politics, economics, and a doctors office. Subscribe for more great content and check out the articles at www.FLATLINING.net.
Episode details
Comments
a man holding his stomach with his hands
Photo by Towfiqu barbhuiya on Unsplash

This week on the FLATLINING Podcast, Matthew and Ron discuss the new weight loss drug by Novo Nordisk (NVO 0.00) called Wegovy and how it and similar drugs could change America’s public health. Plus, they talk about why insurance companies aren’t covering it and how and when that could change.

Share

Subscribe to the FLATLINING Podcast on Apple Podcasts, Spotify, the iHeartRadio app, Amazon Music, Google Podcasts, Stitcher, Pandora, TuneIn, and Audible.

Articles mentioned in this program:

Ozempic Can Cause Major Weight Loss. What Happens if You Stop Taking It? - The New York Times

What to Know About Ozempic, Wegovy and the New Weight-Loss Market - CNET

Covering new weight loss drugs could strain Medicare, policy experts warn - STAT News

Share